GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » Cyclically Adjusted PB Ratio

Regulus Therapeutics (STU:7RG0) Cyclically Adjusted PB Ratio : 0.02 (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Regulus Therapeutics's current share price is €1.98. Regulus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €89.47. Regulus Therapeutics's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for Regulus Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:7RG0' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.03
Current: 0.02

During the past years, Regulus Therapeutics's highest Cyclically Adjusted PB Ratio was 0.03. The lowest was 0.00. And the median was 0.00.

STU:7RG0's Cyclically Adjusted PB Ratio is ranked better than
96.82% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs STU:7RG0: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regulus Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €1.512. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €89.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regulus Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Regulus Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Cyclically Adjusted PB Ratio Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.03 0.01 0.01

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.03

Competitive Comparison of Regulus Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Regulus Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Cyclically Adjusted PB Ratio falls into.



Regulus Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regulus Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.98/89.47
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regulus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regulus Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.512/131.7762*131.7762
=1.512

Current CPI (Mar. 2024) = 131.7762.

Regulus Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 167.104 100.560 218.978
201409 158.805 100.428 208.376
201412 262.493 99.070 349.151
201503 320.708 99.621 424.224
201506 275.175 100.684 360.152
201509 257.097 100.392 337.471
201512 259.516 99.792 342.692
201603 218.950 100.470 287.173
201606 179.347 101.688 232.413
201609 146.846 101.861 189.973
201612 120.531 101.863 155.927
201703 81.707 102.862 104.674
201706 40.155 103.349 51.200
201709 47.051 104.136 59.540
201712 34.351 104.011 43.521
201803 21.341 105.290 26.710
201806 10.263 106.317 12.721
201809 1.545 106.507 1.912
201812 -5.836 105.998 -7.255
201903 -4.965 107.251 -6.100
201906 2.016 108.070 2.458
201909 -0.062 108.329 -0.075
201912 8.569 108.420 10.415
202003 4.884 108.902 5.910
202006 2.121 108.767 2.570
202009 1.680 109.815 2.016
202012 3.172 109.897 3.804
202103 3.049 111.754 3.595
202106 3.512 114.631 4.037
202109 2.833 115.734 3.226
202112 3.332 117.630 3.733
202203 3.062 121.301 3.326
202206 2.738 125.017 2.886
202209 2.379 125.227 2.503
202212 1.866 125.222 1.964
202303 1.473 127.348 1.524
202306 1.610 128.729 1.648
202309 1.309 129.860 1.328
202312 0.960 129.419 0.977
202403 1.512 131.776 1.512

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regulus Therapeutics  (STU:7RG0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regulus Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (STU:7RG0) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (STU:7RG0) Headlines

No Headlines